New drugs in recurrent high grade gliomas

Alba Ariela Brandes, Lara Maria Pasetto, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review


Background: The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration. Materials and Methods: This article analyzes the new drugs that have been introduced for the treatment of these patients in recent years, the objective response, the TTP and the MST. Results: The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years. Conclusion: New approaches to chemotherapy treatment are necessary. Enrollment of patients into rigorous, well-conducted, clinical trials, both at tumor diagnosis and after tumor recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.

Original languageEnglish
Pages (from-to)1913-1920
Number of pages8
JournalAnticancer Research
Issue number3 B
Publication statusPublished - 2000


  • Brain tumors
  • Chemotherapy
  • Glioblastoma
  • Recurrence
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'New drugs in recurrent high grade gliomas'. Together they form a unique fingerprint.

Cite this